Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. Neil E. Kay, MD
|
|
Give Review
Doctor Neil E. Kay, MD practices Hematology. He went to Mount Sinai School of Medicine. Doctor Neil E. Kay, MD has written publications. He has 101 publications published with PubMed. The lastest publication is: 'The Dohner fluorescence insitu hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.
- Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.
- Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression.
- BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.
- Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.
- Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia.
- Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia.
- A novel method for analysis of human T cell repertoires by real-time PCR.
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia.
- Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
- The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in...
- Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.
- Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.
- How we treat Richter syndrome.
- Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling.
- The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.
- Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia.
- Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
- Extramedullary chronic lymphocytic leukemia: Systematic analysis of cases reported between 1975 and 2012.
- Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
- Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.
- Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.
- Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia.
- Long-term repair of T-cell synapse activity in a phase 2 trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic...
- Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab an...
- CGH Protocols: Chronic Lymphocytic Leukemia.
- Mapping of the IRF8 Gene Identifies a 3'UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes.
- Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls.
- Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
- Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- A Phase I Clinical Trial of CpG Oligonucleotide 7909 (PF-03512676) in Patients with Previously Treated Chronic Lymphocytic Leukemia.
- Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.
- Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
- Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.
- GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma.
- The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications ...
- Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.
- Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.
- Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
- Maintenance therapy for B-chronic lymphocytic leukemia.
- Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma.
- Differentiation of Chronic Lymphocytic Leukemia B Cells into Immunoglobulin Secreting Cells Decreases LEF-1 Expression.
- Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.
- Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.
- Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma.
- LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.
- Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: impl...
- Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.
- Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.
- Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
- Genetic susceptibility variants for chronic lymphocytic leukemia.
- Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.
- CD5-positive chronic B-cell lymphoproliferative Disorders: diagnosis and prognosis of a heterogeneous disease entity.
- Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell ad...
- Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.
- Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.
- Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
- De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
- Pentostatin treatment combinations in chronic lymphocytic leukemia.
- Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells.
- B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.
- Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.
- Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG.
- Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
- Validation of a new prognostic index for patients with chronic lymphocytic leukemia.
- Familial chronic lymphocytic leukemia: what does it mean to me?
- The yin and yang of lenalidomide.
- Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
- Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
- Benefits of minimal residual disease negativity in the therapy of chronic lymphocytic leukemia.
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
- Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
- Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD4...
- Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.
- Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.
- Community-based phase II trial of PCR for CLL/SLL patients.
- Chronic lymphocytic leukemia: biology and current treatment.
- Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic...
- Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
- Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test.
- Prognostic factors in chronic lymphocytic leukemia.
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untre...
- Comprehensive management of the CLL patient: a holistic approach.
- Chronic lymphocytic leukemia: current and emerging treatment approaches.
- Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.
- Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
- Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-termin...
- Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia.
- Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.
- Complete response in multiple Myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
- Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.
- Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.
- The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia.
- Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative Disorders.
- Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents.
- Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS.
- Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
- Highlights from the 46 th annual meeting of the American Society of Hematology.
- Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.
Schools
University Of Manitoba Faculty Of Medicine
Conditions Treated
- Anemia
- Myeloma
- Myeloproliferative Disorders
- Pancytopenia
Doctors Specialties
- Hematology
Accepted Insurances
Education
-
Mount Sinai School of Medicine -
SUNY Upstate Medical University -
University of Manitoba
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1073585048 | |
| NPPES Provider LastName | KAY | |
| NPPES Provider FirstName | NEIL | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology | |
| Total Claim Count | 30.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073585048 |
| Last Name Of The Provider | KAY |
| First Name Of The Provider | NEIL |
| View All |
Similar Doctors
|
|
Dr. Ayalew Tefferi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen M. Ansell, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. C Christopher Hook, MD |
|
|
Dr. Rafael Santana-Davila, MD |
|
|
Dr. Shaji K. Kumar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle A. Elliott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arleigh B. Robertson McCurdy, MD |
|
|
Dr. Paul D. Brown, MD |
|
|
Dr. Linda N. Dao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica L. Geiger, MD |
|
|
Dr. William R. Macon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amie E. Jackson, MD |
|
|
Dr. Tait D. Shanafelt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nanna H. Sulai, MD |
|
|
Dr. Jeremy C. Jones, MD |
|
|
Dr. David B. Zhen, MD
This Doctor is OpenDoctor Recommended.
|